Skip to main content
Clinical Trials/NCT02127281
NCT02127281
Completed
Not Applicable

Randomized Controlled Trial of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Knee and Hip Revision Arthroplasty.

The Cleveland Clinic1 site in 1 country160 target enrollmentMay 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prosthesis-related Infections
Sponsor
The Cleveland Clinic
Enrollment
160
Locations
1
Primary Endpoint
Number of Patients With Wound Complications
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to determine the efficacy of a negative pressure wound therapy (NPWT) system after revision total knee and hip arthroplasty in patients at high risk for infection. It is hypothesized that the use of NPWT system (i.e., Prevena) in high risk patients prevents wound complications and decreases reoperation rates.

Detailed Description

One of the primary causes of un-planned readmission following lower extremity arthroplasty procedures is infection. Continuous wound drainage poses a serious risk for infection and is often initially treated with absorbent dressings and/or oral antibiotics. Comorbidities such as obesity, diabetes and tobacco abuse predisposes to wound complications and therefore infection after these procedures. NPWT has proven to be effective for postoperative drainage and decreases the risk for infection or further reoperation. This prospective randomized trial will involve 160 patients at high risk for infection undergoing revision total knee or hip arthroplasty; 80 patients will be randomly selected to be treated with the NPWT system (Prevena) and randomly selected to be treated with the current standard of care wound dressing (control group). Patients will be enrolled at a single site of the Cleveland Clinic Health System (Main Campus).

Registry
clinicaltrials.gov
Start Date
May 2014
End Date
June 30, 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Carlos Higuera-Rueda

Staff, Adult Reconstruction

The Cleveland Clinic

Eligibility Criteria

Inclusion Criteria

  • Scheduled revision Total Hip or Knee Arthroplasty Procedure
  • Presence of one of the following: body mass index (BMI) greater than 35, use of blood thinners other than acetylsalicylic acid (ASA) after surgery, peripheral vascular disease, depression, diabetes mellitus, current tobacco use, history of prior infection, current use of immunomodulators or steroids, current history of cancer or hematological malignancy, rheumatoid arthritis, renal failure or dialysis, malnutrition, liver disease, transplant status, or HIV.

Exclusion Criteria

  • Patient lives \>100 miles from hospital
  • Patient is \< 18 years old
  • Silver allergy

Outcomes

Primary Outcomes

Number of Patients With Wound Complications

Time Frame: Within 90 days after surgery

Any wound complications including but not limited to drainage, blisters, cellulitis, superficial infection, and deep infection.

Re-operation Rates

Time Frame: Within 90 days after surgery

Number of patients who required re-operations that were related to the revision arthroplasty and occurred within 90 days of the revision

Readmission Rates

Time Frame: Within 90 days after surgery

Number of patients who had hospital readmission(s) related to the revision surgery that occurred within 90 days of revision

Secondary Outcomes

  • Knee Flexion(4 weeks postoperative)
  • Hip Range of Motion(4 weeks postoperative)
  • HOOS and KOOS Scores at 90 Days Postoperatively(90 days postoperative)
  • Hip Range of Motion (Flexion)(4 weeks postoperative)
  • Knee Extension(4 weeks postoperative)
  • Timed-up-and-go Test(4 weeks postoperatively)
  • VR-12 Questionnaire(90 days postoperatively)

Study Sites (1)

Loading locations...

Similar Trials